medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2019, Number 1

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2019; 35 (1)

B-cell chronic lymphoid leukemia: a review of its etiopathogenic, molecular and prognostic aspects

Triana MY, Marsán SV, Sánchez BA, Díaz DG

Language: Spanish
References: 29
Page: 1-14
PDF size: 138.21 Kb.


ABSTRACT

Chronic lymphocytic leukemia (CLL) is a malignancy that mainly affects middle-aged and elderly patients. It is characterized by the proliferation of morphologically mature but immunoincompetent lymphocytes that accumulate in blood, bone marrow and lymphatic tissue. It presents great clinical heterogeneity. Several phenotypes are described, although the clonal expansion of CD5 + CD23 + B cells predominates. Prognostic factors include the cytogenetic subgroup, immunoglobulin mutational status, expression of ZAP-70, CD38, and CD49d. The treatment is based on using modern approved therapeutic algorithms that produce greater responses and minor secondary events, to achieve complete clinical remission and to improve the quality of life of these patients.


REFERENCES

  1. Arias Segura JO, González Valero JM. Leucemia linfocítica crónica. LUX MÉDICA. 2013;8(25):29-38. [ Links ]

  2. Sarmiento MA, Palacios MF, Scolnik MP, Ramírez F, Stanganelli C, Cabrera J, et al. Evolución de la leucemia linfática crónica. Valor predictivo del inmunofenotipo, el CD23 soluble y la morfología. Medicina (B. Aires). 2002;62(4):305-12. [ Links ]

  3. Martín GP, Puerta JM, Chacón MJ. Leucemia linfática crónica B. Diagnóstico, pronóstico y tratamiento. Actual Med. 2017;100:(800):52-3. DOI: 10.15568/am.2017.800.ao01 [ Links ]

  4. Valdespino-Gómez VM. Leucemia linfocítica crónica de linfocitos B: un modelo personalizado de valoración clínica y molecular. Rev Hematol Mex. 2014;15:103-21. [ Links ]

  5. Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, Yu X , et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med. 2001;194:639-47. [ Links ]

  6. Kipps TJ. Immunoglobulin genes in chronic lymphocytic leukemia. Blood Cells. 1993;19:615-25. [ Links ]

  7. Stamatopoulos K. Antigens in CLL: themes and variations. Blood. 2010;115:3855-6. [ Links ]

  8. Steininger C, Widhopf GF, Ghia EM, Morello CS, Vanura K, Sanders R, et al. Recombinant antibodies encoded by IGHV1-69 react with pUL32, a phosphoprotein of cytomegalovirus and B cell superantigen. Blood. 2012;119:2293-2301. [ Links ]

  9. Puente XS, Pinyol M, Quesada V, Conde L, Ordóñez GR, Villamor N, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature. 2011 Jun 5;475(7354):101-5. doi: 10.1038/nature10113 [ Links ]

  10. Woyach JA, Johnson AJ, Byrd JC. The B cell receptor signaling pathway as a therapeutic target in CLL. Blood. 2012;120:1175-84. [ Links ]

  11. Buggins AG, Levi A, Gohil S, Fishlock K, Patten PE, Geyer SM, et al. Evidence for a macromolecular complex in poor prognosis CLL that contains CD38, CD49d, CD44 and MMP-9. Br J Haematol. 2011;154:216-22. [ Links ]

  12. Zhang S, Wu CCN, Fecteau J-F, Cui B, Chen L, Zhang R, et al. Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44. Proc Natl Acad Sci USA. 2013;110:6127-32. [ Links ]

  13. Suping Z, Kipps JT. The Pathogenesis of Chronic Lymphocytic Leukemia. Ann Rev Pathol. 2014;9:103-18. doi:10.1146/annurev-pathol-020712-163955. [ Links ]

  14. Cuneo A, Cavazzini F, Ciccone M, Daghia G. Modern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high-risk subgroups. Cancer Med. 2014;3:555-64. [ Links ]

  15. Villegas-Gracia R, Franco-Alzate C, Jaramillo-Arbeláez P. Linfocitosis monoclonal de células B: una revisión de aspectos generales. Rev CES Med. 2015;29(2):227-38. [ Links ]

  16. Rozovski U, Hazan-Halevy I, Keating MJ, Estrov Z. Personalized medicine in CLL: Current status and futureperspectives. Cancer Lett. 2014;352:4-14. [ Links ]

  17. Muhammad AM. Chronic Lymphocytic Leukemia. Medscape 2017. Updated: Jul 16, 2017. (Citado:29/07/2017) Disponible en: Disponible en: https://emedicine.medscape.com/article/199313-overview [ Links ]

  18. Van Dongen J, Adriaasen HJ. Immunobiology of leukemia. Leucemia. 6th ed. Philadelphia: WB Saunders 2016, p. 83-130. [ Links ]

  19. Pui CH, Behm FG, Crist WM. Clinical and biologic relevance of immunologic marker studies in childhood acute lymphoblastic leukemia. Blood. 2013; 82(2):343-62. [ Links ]

  20. Drenon B, Fardel O, Fauchet R, Amiot J. Flowcytometry: application for the diagnosis and the follow-up of hematological malignancies. Ann Biol Clin. 2013; 60(6):663-72. [ Links ]

  21. Pagnucco G, Vanelli L, Gervasi F. Multidimensional flow cytometry immunophenotyping of hematologic malignancy. Ann N Y Acad Sci. 2013; 963:313-21. [ Links ]

  22. Sandes AF, de Lourdes Chauffaille M, Oliveira CR. CD200 has an important role in the differential diagnosis of mature B-cell neoplasms by multiparameter flow cytometry. Cytometry B Clin Cytom. 2014; 86:98-105. [ Links ]

  23. Dragović IT, Kraguljac KN, Knežević V, Bogdanović A, Biljana Mihaljević B, Božić B, et al. The Role of Immunophenotyping in Differential Diagnosis of Chronic Lymphocytic Leukemia. Srp Arh Celok Lek. 2014 Mar-Apr;142(3-4):197-203. DOI: 10.2298/SARH1404197D. [ Links ]

  24. Piedras J. Citometría de flujo en el diagnóstico y clasificación de padecimientos hematológicos: leucemias agudas, síndromes linfoproliferativos crónicos y glicoproteínas plaquetarias. Rev Hematol Mex. 2006;7(2):53-62. [ Links ]

  25. Falchi L, Keating MJ, Marom EM, Truong MT. Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia. Blood. 2014;123:2783-90. [ Links ]

  26. Furman RR, Sharman JP, Coutre SE. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. New Engl J Med. 2014; 370(11):997-1007. [ Links ]

  27. Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse F, et al, eds. SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, basado en la presentación de datos de SEER en noviembre de 2013, publicados en el sitio web de SEER en 2014. (Consultado: 09/06/2014). Disponible en: Disponible en: http://www.seer.cancer.gov/csr/1975_2011/ [ Links ]

  28. Jones JA, Byrd JC. How will B-Cell receptor targeted therapies change future cell therapy? Blood. 2014;123(10):1455-60. [ Links ]

  29. Mertens D, Stilgenbauer S. Prognostic and predictive factors in patients with chronic lymphocytic leukemia: Relevant in the era of novel treatment approaches? J Clin Oncol. 2014;32:869-72. [ Links ]




2020     |     www.medigraphic.com